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Little is known about the long-term clinical outcomes for human immunodeficiency virus (HIV)–infected
patients who have received highly active antiretroviral therapy (HAART). Determining factors associated with
long-term clinical outcomes early in the course of treatment may allow modifications to be made for patients
who are at a greater risk of treatment failure. To evaluate these factors, we studied 213 HIV-infected patients
who had received HAART for at least 115 weeks. In the univariate analysis, virological response, which was
measured as the change in virus load from baseline at month 3 of treatment, was the single best predictor of
clinical outcome (relative hazard, 0.722; ), independent of virological suppression. In the multivariatePp .001
analysis, virological response and immunologic response, which was measured as an increase in CD4 cell count
of 1200 cells/mm3, resulted in better prediction of clinical outcomes than did use of either variable alone
( ). Our results indicate that changes in virus load and immunologic response together are goodPp .02
predictors of clinical outcome and can be assessed after the initiation of HAART, which would allow clinicians
to identify patients early in the course of therapy who are at greater risk of negative outcome.
The use of highly active antiretroviral therapy (HAART)
with combinations of reverse-transcriptase and protease
inhibitors to manage HIV disease has led to dramati-
cally reduced morbidity and prolonged life among HIV
type 1 (HIV-1)–infected patients [1, 2]. The initiation
of HAART rapidly and significantly reduces the levels
of virus replication in the peripheral blood [3–5]. In
the HIV-infected patient, higher baseline levels of HIV
RNA and lower baseline levels of CD4 T lymphocyte
cells in the peripheral blood are strongly predictive in-
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dicators of disease progression [6, 7]. However, these
and other prognostic indices are poorly defined for pa-
tients who have received long-term HAART and for
patients who receive salvage therapy.
In the clinical setting, virological treatment failure
occurs for many patients, prompting the administration
of salvage therapy with a different combination of drugs
[8, 9]. Virological treatment failure may be due to non-
adherence, toxicity, intolerance, or emergence of drug-
resistant mutations [10–13]. Examination of clinical
outcomes for patients who have received long-term
HAART can yield insights into the predictive power of
surrogate markers. Use of the markers can identify,
early on, patients who are at higher risk of clinical
failure. For patients deemed to be at higher risk, mod-
ification or intensification of therapy may be necessary.
The factors that have previously been associated with
progression of HIV disease are baseline quantitative
HIV-1 RNA levels, baseline CD4 T cell counts [6, 7,
14–20], virus load at the nadir [21, 22], CD4 T cell
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Table 1. Characteristics of the 213 HIV-infected patients at
baseline.
Characteristic
No. (%) of patientsa
(n p 213)
Sex
Male 195 (92)
Female 18 (8)
Age, median years (range) 41 (21–69)
Clinical stage
Asymptomaticb 85 (40)
Symptomaticc 87 (41)
Clinical AIDSd 41 (19)
CD4 T cell count, cells/mm3
Median (range) 230 (0–1011)
0–99 43 (20)
100–199 45 (22)
200–399 80 (36)
1400 45 (22)
HIV RNA, median log copies/mL (range) 4.239 (1–5.8)
Experience with reverse-transcriptase
inhibitors
Antiretroviral naı¨ve 37 (17)
“Moderate” or !3 drugs 144 (68)
“Heavy” or 3 drugs 32 (15)
a Unless otherwise indicated.
b Centers for Disease Control and Prevention (CDC) stage A.
c CDC stage B.
d CDC stage C.
counts of 1200 cells/mm3 at month 3 after the initiation of
HAART [23], and area under the curve (defined as the sum of
the area underneath the virus load curve between 2 points; area
under the curve can also be used to measure the change in
virus load) [24]. Several studies have analyzed the effects of
long-term HAART on virological and immunologic responses.
Deeks et al. [25] found that sustained CD4 T cell response
was related to changes in HIV RNA levels to below pretreatment
baseline levels, and that even transient or partial decreases in
virus levels can have sustained effects on CD4 T cell counts.
Mezzaroma et al. [26] described discordant immunologic and
virological responses in patients who had undergone treatment
with multiple drugs. They found a decreased risk of mortality
and immunologic benefit for patients who were receiving
HAART, even in the absence of sustained viral suppression.
Our study examines virological response and immunologic re-
sponse as predictors of clinical outcome for patients who have
received long-term HAART. We relate immunologic and vi-
rological factors and their interaction, as well as disease stage
and pretreatment with antiretroviral agents, to virological and
clinical failure.
We found that changes in virus load to below baseline lev-
els—not the level of virological suppression—was the most
important factor in the determination of clinical outcome. We
also found that virological response and immunologic response
together are good predictors of clinical outcome and can be
assessed early in the course of HAART, which allows for the
early identification of patients who are at greater risk of negative
clinical outcomes.
SUBJECTS AND METHODS
Study subjects. A 20% random sample was taken from the
entire HIV-positive clinic population in an outpatient clinic in
Los Angeles. The random sample was generated on the basis
of the unique patient identification numbers that are used
within the clinic. Inclusion criteria were the following: (1) in-
itiation of HAART before June 1997 (to allow at least 115 weeks
of observation) and (2) availability of HIV RNA levels and CD4
T cell counts that were recorded before the patients began
receiving HAART.
Seven patients were excluded from the study because they
were not receiving or had stopped receiving HAART. The ex-
cluded patients did not differ significantly from the included
patients with regard to age, sex, CD4 T cell count at baseline,
virus load at baseline, or disease stage. A total of 213 patients
were included in the study and were observed for at least 115
weeks (range, 115–153 weeks). Risk factors for transmission
were homosexual contact (194 patients [91%]), heterosexual
contact (17 patients [8%]), and injection drug use (2 patients
[1%]). Patients had regular follow-up visits and had a high
level of self-reported adherence. Consent was given under the
condition that the anonymity of the patients be preserved.
The study population consisted of 195 men and 18 women.
Table 1 lists the characteristics of the patients at baseline. The
“baseline value” is defined as the average of 2 consecutive mea-
surements taken before the start of the first HAART regimen.
The median age at baseline was 41 years. Plasma HIV-1 RNA
levels, which were measured by use of an ultrasensitive assay
with a quantification limit of 20 copies/mL (Immune Diag-
nostic Laboratory), and CD4 T cell counts, which were assessed
by means of flow cytometry (Becton Dickinson), were deter-
mined monthly. Median HIV-1 RNA level at baseline was 4.239
log copies/mL (range, 1–5.8 log copies/mL). The median base-
line CD4 T cell count was 230 cells/mm3 (range, 0–1011 cells/
mm3). Thirty-seven patients (17%) were antiretroviral naı¨ve.
Thirty-two patients (15%) had received 3 reverse-transcrip-
tase inhibitors before they started receiving HAART. Oppor-
tunistic infections were diagnosed in 41 patients before they
began receiving HAART.
All patients were receiving individualized treatment regi-
mens, and all received HAART continuously for at least 115
weeks. Table 2 lists the most common initial HAART regimens.
For this study, HAART was defined as the administration of a
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Table 2. Most common initial regimens of
highly active antiretroviral therapy.
Regimen
No. of
patients
Two RTIs and indinavir 69
Two RTIs, saquinavir, and ritonavir 47
Two RTIs and saquinavir 44
Two RTIs and nelfinavir 35
Two RTIs, nelfinavir, and saquinavir 12
One RTI, ritonavir, and saquinavir 6
NOTE. RTI, reverse-transcriptase inhibitor.
Table 3. Relative hazards (RHs) of virological failure and 95%
CIs from the Cox proportional hazards model.
Model covariate RH (95% CI) P
Previous OI 5.334 (3.784–7.456) .0001
Baseline virus load 1.591 (1.202–2.104 .0012
Baseline CD4 T cell count 0.938 (0.918–0.969) .0182
Treatment naı¨ve 0.625 (0.387–0.989) .054
NOTE. OI, opportunistic infection.
combination of 3 antiretroviral agents, among which at least
1 antiretroviral agent was a protease inhibitor. For many pa-
tients (156 patients), it was necessary to administer a salvage
regimen that consisted of different combinations of antiretro-
viral agents because of intolerance (in 43 patients) or increasing
plasma HIV-1 RNA levels (in 113).
Clinical end points. “Virological suppression” was defined
by a virus load measurement of !100 copies/mL. “Virological
failure” was defined by 2 consecutive virus load measurements
of 1500 copies/mL. “Clinical failure” was defined by diagnosis
of an AIDS-defining illness or death, regardless of CD4 T cell
count. For patients who had an opportunistic infection diag-
nosed before the start of the HAART regimen (41 patients),
“clinical failure” was defined as relapse of the opportunistic
infection or onset of a new AIDS-defining illness.
Statistical analysis. For time-to-event analysis, we used
the Kaplan-Meier method and the Cox proportional hazards
model. Survival time was measured from the date of initiation
of HAART to the occurrence of an AIDS-defining event or
censoring time (i.e., end of study). Comparisons of survival
rates across subgroups were performed by use of the log-rank
test and the Cox proportional hazards model. Associations
among subgroups were examined by use of Kaplan-Meier plots
and proportional hazards models, including partial likelihood
ratio x2 statistics. All P values are 2-sided.
Statistical and graphic testing showed that the proportional
hazards assumption was not violated. Data were analyzed by
use of SAS software, version 6.11 (SAS Institute).
Potential predictors of long-term clinical outcome included
virological response (measured as change in virus load between
baseline and month 3 of HAART), immunologic response (CD4
T cell count of 1200 cells/mm3 at month 3 of HAART), change
in CD4 T cell count at month 3 of HAART, interaction between
virological and immunologic parameters, virus load at the na-
dir, baseline virus load, baseline CD4 T cell count, virus load
as a continuous variable, CD4 as a continuous variable, stage
of disease, and pretreatment with antiretroviral agents prior to
the commencement of HAART.
RESULTS
We analyzed 213 patients in an outpatient clinic who had re-
ceived HAART for at least 115 weeks. The characteristics of
the 213 subjects are listed in table 1.
Virological suppression. “Virological suppression” was de-
fined as an HIV-1 RNA level of !100 copies/mL. “Virological
rebound” was defined as 2 consecutive virus load measurements
of 1500 copies/mL that occurred after virological suppression.
The virological suppression rate was 69% (147 of 213 patients).
Of the 66 patients in whom virological suppression did not occur,
63 (95%) were pretreated and 3 (5%) were treatment naı¨ve.
Of the 147 patients in whom virological suppression was
achieved, 56 (38%) had a rebound in virus load by the end of
the 115-week period. Of the 110 pretreated patients, 49 (45%)
had a rebound in virus load, whereas only 7 (19%) of the 37
treatment-naı¨ve patients had a viral rebound. Predictors of vi-
rological failure were baseline virus load, baseline CD4 T cell
count, history of experience with antiretroviral agents, and his-
tory of opportunistic infection. Table 3 lists the relative hazards
and 95% CIs of virological failure from the Cox proportional
hazards model.
Predictors of clinical failure. During the 115 weeks of fol-
low-up, 71 patients (33%) had conditions that progressed to an
AIDS-defining event or death due to an AIDS-related cause. Table
4 lists the frequencies of the clinical end points that occurred.
We tested whether the initial virological response was predictive
of clinical failure. Virological response was measured as the
change in HIV-1 RNA levels from baseline after 3 months of
HAART. (Note that with 2 timepoints, this method yields the
same information as area under the curve.) Subjects who had
more dramatic virological responses (i.e., greater decreases in
HIV RNA levels from baseline at month 3) had a lower risk of
progression than did those who had a more modest response
(relative hazard [RH], 0.722; 95% CI, 0.5931–0.8407; Pp
). Therefore, for each decrease in HIV-1 RNA level of 1.0.0001
log copies/mL that occurred after the initiation of HAART, the
hazard of clinical failure decreased by an estimated 27.8%.
To analyze this result more closely, patients were stratified
according to initial virological response into the categories of
“high,” “moderate,” and “low.” High virological responders had
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Table 4. Frequencies of clinical end points.
Clinical end point
No. (%) of
patientsa
Wasting 17 (24)
Cytomegalovirus infection 10 (14)
Mycobacterium avium complex infection 8 (11)
Cryptosporidiosis 7 (10)
Kaposi’s sarcoma 7 (10)
Death 7 (10)
Encephalopathy 4 (6)
Pneumocystis carinii pneumonia 2 (3)
Progressive multifocal leukoencephalopathy 2 (3)
Toxoplasmosis 2 (3)
AIDS dementia 2 (3)
Esophageal candidiasis 2 (3)
Recurrent pneumonia 1 (1)
a Some patients experienced 11 clinical end point.
Figure 1. Kaplan-Meier estimates of the proportion of subjects who
did not reach the primary clinical end point (i.e., clinical failure), among
subjects stratified according to virological response. The Y-axis shows
the proportion of patients left in the sample who did not have clinical
failure. The solid line represents the survival curve for patients with a
low initial response to highly active antiretroviral therapy (HAART). The
short-dashed line represents the survival curve for patients with a mod-
erate initial response to HAART. The long-dashed line shows the survival
curve of patients with a high initial response to HAART ( forPp .001
the comparison between subject groups).
a decrease in virus load of 11.0 log copies/mL by month 3 after
the initiation of HAART. Moderate virological responders had
a decrease in virus load of 0.5 log copies/mL to 1.0 log copies/
mL. Low virological responders had a decrease in virus load of
!0.5 log copies/mL after 3 months of HAART. Kaplan-Meier
curves were constructed with use of these strata and are shown
in figure 1. Differences in the strata were statistically significant,
according to the log-rank test ( ). Furthermore, base-Pp .0001
line virus load was not significant as a predictor of clinical
failure for recipients of long-term HAART ( ).Pp .4280
A previous study by d’Arminio Monforte et al. [23] found
that CD4 T cell counts of 1200 cells/mm3 at month 3 of HAART
were predictive of clinical outcome. In univariate analysis, CD4
T cell response, which was measured as a CD4 T cell count of
1200 cells/mm3 at month 3 of HAART, was significant at
. However, in multivariate analysis, virological re-Pp .001
sponse was found to be a better predictor of clinical outcome
(virological response: RH, 0.278; 95% CI, 0.1678–0.4598;
; CD4 T cell response: RH, 0.562; 95% CI,Pp .0001
0.3482–0.9061; ). Table 5 lists the relative hazards ofPp .0181
clinical failure and the 95% CIs from the multivariate Cox
proportional hazards model.
Although virological response was superior to immunologic
response as a predictor of clinical outcome, we found that
combining the virological and immunologic information in the
same analysis yielded a better predictor than did use of either
variable alone ( , by use of the likelihood ratio test).Pp .02
Patients with both a virological and an immunologic response
at month 3 of HAART had a hazard of failure that was only
39% of that for patients who had a discrepant response (RH,
0.3947; 95% CI, 0.3056–0.5157; ). To better illustratePp .0001
this result, patients were stratified by their virological and CD4
T cell response as follows: patients with a virological response
(decrease in virus load of 11.0 log copies/mL by month 3 of
HAART) and CD4 T cell response (CD4 T cell count of 1200
cells/mm3 by month 3 of HAART), virological response only,
CD4 T cell response only, and no response. The Kaplan-Meier
curves are presented in figure 2.
In both univariate and multivariate analyses, baseline CD4 T
cell count was an important predictor of disease progression for
this patient group. Patients with higher baseline CD4 T cell
counts had a decreased risk of progression (RH, 0.884; Pp
). Baseline CD4 T cell counts were then stratified into clin-.001
ically useful categories (!100 cells/mm3, 100–199 cells/mm3,
200–400 cells/mm3, and 1400 cells/mm3). A Cox proportional
hazards model was used to estimate the relative hazard of pro-
gression on the basis of baseline CD4 T cell count. Subjects who
had CD4 T cell counts of !100 cells/mm3 at the time of initiation
of HAART were nearly 10 times more likely to have progression
to AIDS than were subjects whose CD4 T cell counts were 1400
cells/mm3 (RH, 9.992; ). Compared with subjects whoPp .0001
had CD4 T cell counts of 1400 cells/mm3, subjects with CD4 T
cell counts that were between 100 cells/mm3 and 199 cells/mm3
were 14 times more likely to have progression to AIDS (RH,
4.221; ), and subjects with counts that were betweenPp .001
200 cells/mm3 and 400 cells/mm3 were 3 times more likely to
have progression to AIDS (RH, 2.991; ). The Kaplan-Pp .01
Meier curves are presented in figure 3.
Although baseline CD4 T cell count was significant, changes
in CD4 T cell counts at month 3 and over the course of time
were not statistically significant ( ). Other univariate pre-P 1 .05
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Table 5. Relative hazards (RHs) of clinical failure and 95% CIs
from the multivariate Cox proportional hazards model.
Model covariate RH (95% CI) P
Virological response 0.278 (0.1678–0.4598) .0001
Immunologic response 0.562 (0.3482–0.9061) .0181
Previous OI 3.326 (2.440–4.525) .051
Treatment naı¨ve 0.874 (0.447–1.7083) .593
Nadir virus load 0.921 (0.823–1.464) .351
NOTE. OI, opportunistic infection.
Figure 2. Kaplan-Meier estimates of the proportion of subjects who
did not reach the primary clinical end point (i.e., clinical failure), among
subjects stratified according to the following immunovirological responses:
virological and immunologic response, virological response alone, im-
munologic (CD4 T cell) response alone, and no response. The Y-axis shows
the proportion of patients left in the sample who did not experience
clinical failure. HAART, highly active antiretroviral therapy.
dictors of clinical outcome were virus load at the nadir (RH,
1.348; ), history of opportunistic infection (RH, 5.415;Pp .002
), and no history of antiretroviral treatment (RH,Pp .001
0.417; ). However, none of these variables predictedPp .039
long-term clinical outcome as well as did virological response
and immunologic response combined.
DISCUSSION
The administration of HAART to HIV-infected patients has led
to dramatically decreased rates of morbidity and mortality.
However, the failure of HAART to eradicate HIV [27, 28] leaves
the patient vulnerable to the emergence of drug-resistant strains
of the virus and resurgence of viral replication [29]. Wong et
al. [29] found that the persistence of even low levels of de-
tectable virus in the peripheral blood as a result of incomplete
viral suppression reflects ongoing replication in the lymphoid
system and the emergence of drug resistance.
We conducted this study to assess the factors that are as-
sociated with long-term HAART administered in an outpatient
setting. We found that HAART was initially able to suppress
viral replication in the majority of patients, more so for patients
who were treatment naı¨ve. However, we found that viral sup-
pression was not sustained in 56 (38%) of the patients. The
resulting viral rebound led to modification of the therapy regi-
mens. This pattern of incomplete and transient virus suppres-
sion has been reported after several studies of clinical popu-
lations [10, 25, 26].
Almost all of the patients (156 of 213) had a rebound in
virus load during administration of HAART, at which time
salvage therapy regimens were instituted. In many instances,
salvage therapy was not sufficient to suppress virus levels. This
was most likely the result of the emergence of drug-resistant
strains of the virus and, in some instances, because of the
patient’s failure to adhere to treatment regimens.
Noncompliance has a critical effect on the outcome of long-
term treatment in an outpatient clinic. Patients who were not
fully compliant, as defined by self-reported adherence, were not
dropped from the study. Thirty percent of the patients ac-
knowledged some noncompliance when questioned by the phy-
sician. The results of this study should be considered in light
of this finding.
Opportunistic infections were diagnosed in 41 patients be-
fore the start of their first HAART regimen. These patients also
had low CD4 T cell counts and were more likely to have been
pretreated with reverse-transcriptase inhibitors. Fifteen patients
(37%) were treated with 3 nucleoside reverse-transcriptase
inhibitors before the commencement of HAART. These patients
accounted for the majority of cases of clinical treatment failure.
Predictors of virological suppression were baseline virus load,
baseline CD4 T cell count, previous experience with antiretro-
viral agents, and history of opportunistic infection. These find-
ings are similar to those of other studies [1, 6, 7, 10–19, 23,
24]. We found that one of the most important predictors of
clinical progression in patients who were receiving long-term
HAART was the initial virological response to HAART. Patients
who have a decrease in virus load of 0.5 log copies/mL (from
baseline) at month 3 of HAART have a decreased risk of clinical
failure. These results suggest that patients with high baseline
virus loads or low CD4 T cell counts may have favorable clinical
outcomes if they have a good virological response to HAART
by month 3 of treatment.
Immunologic response was also an important predictor of
long-term clinical outcome. We looked at CD4 T cell response
in many different ways. CD4 T cell count, both as a continuous
variable and in terms of the change from baseline level, was
not statistically significant. In comparison with changes in virus
load, changes in CD4 T cell count were not dramatic enough
to have great statistical power. By defining “CD4 T cell re-
sponse” as a count of 1200 cells/mm3, we were able to achieve
significance. A CD4 T cell count of 200 cells/mm3 is an im-
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Figure 3. Kaplan-Meier estimates of the proportion of subjects who
did not reach the primary clinical end point (i.e., clinical failure), among
subjects stratified according to baseline CD4 T cell count. The Y-axis
shows the proportion of patients left in the sample who did not experience
clinical failure. The survival curves are based on CD4 T cell counts at
baseline, before the start of highly active antiretroviral therapy (HAART;
for the comparison between subject groups).Pp .01
portant threshold. Below that mark, patients are at increased
risk of development of opportunistic infections and death. This
result is confirmed by the Kaplan-Meier curves for baseline
CD4 T cell count. The variable of immunologic response, as
it was constructed, incorporated this threshold and offered
greater statistical significance in both univariate and multivar-
iate analyses.
Virological response was a better univariate predictor of long-
term clinical outcome than was immunologic response. How-
ever, the combination of virological and immunologic response
was a superior predictor of long-term clinical outcome than
was virological response alone. Because both factors together
offer better predictive power than does either variable alone,
both measurements should be considered in the evaluation of
a patient. Although the result may seem to be contrary to the
findings of d’Arminio Monforte et al. [11], the discrepancy is
due to the fact that we defined virological response as the
change from baseline to month 3 instead of as the mean level
of viremia. Because changes in virus load incorporated infor-
mation about baseline levels and virus load trajectory, they have
more predictive power than do absolute levels of HIV RNA,
such as mean viremia or baseline virus load.
As documented by CD4 T cell response and virological re-
sponse, 94 (44%) of the subjects had a good immunovirological
response to HAART and 62 (29%) had a poor immunovirol-
ogical response. Therefore, 57 (27%) of the patients had a
discordant immunologic or virological response—the so-called
“disconnect.” Thirty-one patients had a good virological re-
sponse, but their CD4 T cell counts did not have a subsequent
increase. Twenty-seven patients had CD4 T cell counts that
increased to 1200 cells/mm3, but their virus loads did not de-
crease to 0.5 log copies/mL from baseline. The Kaplan-Meier
curves in figure 3 show the striking result of the immunovi-
rological response and how it was predictive of clinical out-
come. It also shows an ordering of clinical outcomes according
to response to treatment.
Patients who had a virological response but did not have an
immunologic response were less likely to experience clinical
treatment failure than were patients who had high CD4 T cell
counts and high levels of viremia. This suggests that, although
physicians should look at both virological and immunologic
factors when evaluating patients, the virological response
should weigh more heavily in the decision to modify therapy.
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